Nancy Brown
Showing 1–4 of 4 transcripts.
- Milken Institute54 min
The Next Era of Health | Global Conference 2026
Esther Krofah, Robert Bradway, Nancy Brown, Alicia Jackson, Myechia Minter-Jordan, Dipen Parekh
Addressing a critical demographic tipping point and a $1 trillion caregiver gap, stakeholders including AARP, ARPA-H, and the American Heart Association are reforming U.S. healthcare to bridge the divide between technological innovation and clinical delivery. Initiatives range from deploying agentic AI to extend cardiovascular prevention to counties lacking specialists, to accelerating long-term care research through new regulatory pathways and a target reduction of drug discovery timelines to under five years. Concurrently, global competition drives a strategic pivot toward genomic integration and value-based models, with specific commitments to reduce Lipoprotein(a) levels by 95% and establish federal tax credits for the nation's 63 million caregivers.
- Milken Institute1h 0m
Championing Innovation and ROI in Women's Health Care | Global Conference 2024
Sheryl WuDunn, Nancy Brown, Jocelyn Frye, Kate Ryder, Maria Toler, Olivia Walton
Recent policy shifts and private investments have targeted critical gaps in women's health, following a White House initiative to fund research and a SteelSky-led advocacy push for $12 billion in congressional approval. Despite these efforts, severe disparities persist, including an 18% higher out-of-pocket cost for women, a 20% maternal mortality gap for Black women, and a clinical trial landscape where women of color remain severely underrepresented. Industry leaders and investors are now pivoting toward personalized, lifecycle-focused solutions and "Food is Medicine" models to address systemic barriers while capitalizing on the economic imperative of supporting female health.
- Milken Institute1h 11m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken, Mike Milken, Tom Frieden, Andy Van Eschenbach, Jack Andreyka
A comprehensive analysis of global bioscience reveals a dramatic increase in life expectancy and major breakthroughs in disease eradication, such as the near-elimination of polio and HIV management through programs like PEPFAR. Despite these successes, the sector faces a critical funding crisis where declining NIH grant success rates and inflation-adjusted budget cuts threaten the pipeline of young researchers and the translation of genetic discoveries into new treatments. Strategic initiatives like the Brain Initiative, precision medicine efforts, and the shift toward prevention are now essential to address rising chronic disease burdens and sustain the bioscience industry as a primary driver of US economic growth.
- Milken Institute1h 12m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken
The bioscience forum highlighted the sector's massive contribution to increased global life expectancy and economic growth while emphasizing that flat budgets and inflation have critically reduced NIH grant success rates to below 20%. Distinguished leaders such as Francis Collins and Tom Frieden warned that sustained funding cuts and a 90% treatment-versus-prevention spending imbalance threaten American innovation and the careers of young researchers. Despite these financial constraints, the event underscored significant breakthroughs in areas like genomic medicine and disease eradication, with panelists urging renewed investment to maintain global health leadership and drive future discoveries.